Samsung Pharm & GemVax Present Pancreatic Cancer Immunotherapeutic Drug, RIAVAX Phase III Results at ASCO 2021
Samsung Pharm Co Ltd has announced that the company presented the results of phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called ‘RIAVAX™ (GV1001)’ conducted in Korea at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO 2021, which celebrates its 57th anniversary this year, runs from June 4th to June 8th and will…